NEW YORK (GenomeWeb News) – Sequenom said after the close of the market Friday that it has submitted an offer to the board of directors of Exact Sciences to acquire the firm in an all-stock transaction valued at $41 million.

Under the proposal, each share of Exact Sciences would be exchanged for $1.50 in Sequenom common stock. Sequenom said that offer is subject to a floating exchange rate within a 15 percent collar, in which Sequenom’s stock is trading between $20.74 and $28.06 per share. Sequenom’s shares closed at $23.02 on the Nasdaq, down nearly 6 percent for the day.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.